Picotamide
Picotamide is a platelet aggregation inhibitor. It works as a thromboxane synthase inhibitor and a thromboxane receptor inhibitor, the latter by modifying cellular responses to activation of the thromboxane receptor.[1] Picotamide is licensed in Italy for the treatment of clinical arterial thrombosis and peripheral artery disease.[2]
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
IUPAC name
| |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.046.572 |
Chemical and physical data | |
Formula | C21H20N4O3 |
Molar mass | 376.416 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(verify) |
References
- Ratti, S; Quarato, P; Casagrande, C; Fumagalli, R; Corsini, A (1998). "Picotamide, an antithromboxane agent, inhibits the migration and proliferation of arterial myocytes". European Journal of Pharmacology. 355 (1): 77–83. doi:10.1016/S0014-2999(98)00467-1. PMID 9754941.
- Capra V, Bäck M, Angiolillo DJ, Cattaneo M, Sakariassen KS (2014). "Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation". Journal of Thrombosis and Haemostasis. 12 (2): 126–37. doi:10.1111/jth.12472. PMID 24298905.
External links
- Andrea Celestini and Francesco Violi: A review of picotamide in the reduction of cardiovascular events in diabetic patients (PubMed)
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.